Outcomes
Primary outcomes were frequency and severity of solicited local and systemic AEs 7 and 14 days after each vaccination, respectively; occurrence of unsolicited AEs, AESIs, and SAEs during the entire trial period; and change from baseline for safety laboratory measures.Secondary outcomes were frequency of CD8+ T cells specific to PepGNP-Dengue peptides at baseline, day 21, 35, 90, and 180 after the first vaccination, and antibody titre to all four DENV serotypes.Exploratory outcomes were HLA-related and in-depth characterisation of the dengue-specific CD8+ T cell response.